Weak Demand in Chemical Business Impacts WACKER’s Sales and Earnings Growth in Q2 2023
· GROUP SALES FOR Q2 2023 TOTAL €1.75 BILLION, DOWN 19 PERCENT YEAR OVER YEAR · EBITDA DECLINES 59 PERCENT TO €256 MILLION COMPARED WITH A YEAR EARLIER DUE TO REDUCED VOLUMES AND LOWER PRICES · NET INCOME FOR Q2 2023 AMOUNTS TO €119 MILLION · NET CASH FLOW AT €-99 MILLION, DUE PARTLY TO THE ACQUISITION OF ADL BIOPHARMA AND HIGHER CAPITAL EXPENDITURES · FULL-YEAR FORECAST REVISED: GROUP SALES FOR 2023 LIKELY TO BE BETWEEN €6.5 BILLION AND €6.8 BILLION, EBITDA EXPECTED TO BE BETWEEN €800 MILLION AND €1.0 BILLIONFör mer information se bifogad pressrelease.